Baxter’s HyQvia Clears FDA With Label Warning On Antibody Development
This article was originally published in The Pink Sheet Daily
Product is first subcutaneous immune globulin with once-monthly dosing regimen, but its safety had been a major concern of FDA and elicited a citizen petition.
You may also be interested in...
FDA has three NDAs set for public advisory committee review at the end of March and early April, the first 'real' committee meetings in five months. Oops. Make that two.
FDA’s Amy Abernethy describes how agency’s use of real-world data has evolved in response to COVID-19 and the ‘a-ha’ moment of leveraging different data sources to understand the coronavirus. Takeda R&D President Andrew Plump notes difficulties with platform trials and limitations on data sharing.
If Biden administration wants to nominate the acting commissioner, Vacancies Reform Act would dictate the timing. Woodcock can still get the nod and remain head of the agency during the confirmation process, just as Andrew von Eschenbach retained his acting title following his nomination in 2006.